Single Cell Analysis Reveals Immune Dysfunction from the Earliest Stages of CLL that can be Reversed by Ibrutinib
Getting access
Committee review Health/Medical/Biomedical (HMB)
- Apply at
- https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002705.v1.p1
- Agreement
- Data use agreement
- Cost
- No charge
- Renewal
- Every 1 year
From the operator’s published policy metadata.
About this database
| Last updated | 2026-09-12 |
|---|